A total of seven new small molecule kinase inhibitors have been approved by FDA in 2017. Protein kinases form a very large family of signaling proteins, with more than 500 […]
With upgrading of technologies and better understanding of diseases, the death rate caused by cancers is considerably decreased. According to the 2017 Cancer Progress Report released by the American Association […]
On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (Nerlynx, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer to […]